1
|
Britt V: Manifestations of human
cytomegalovirus infection: Proposed mechanisms of acute and chronic
diseaseHuman Cytomegalovirus. Shenk TE and Stinski MF: Springer
Berlin Heidelberg; Berlin, Heidelberg: pp. 417–470. 2008,
View Article : Google Scholar
|
2
|
Colugnati FA, Staras SA, Dollard SC and
Cannon MJ: Incidence of cytomegalovirus infection among the general
population and pregnant women in the United States. BMC Infect Dis.
7:12007. View Article : Google Scholar
|
3
|
Poole E, McGregor Dallas SR, Colston J,
Joseph RS and Sinclair J: Virally induced changes in cellular
microRNAs maintain latency of human cytomegalovirus in
CD34+ progenitors. J Gen Virol. 92:1539–1549. 2011.
View Article : Google Scholar : PubMed/NCBI
|
4
|
Revello MG, Furione M, Rognoni V, Arossa A
and Gerna G: Cytomegalovirus DNAemia in pregnant women. J Clin
Virol. 61:590–592. 2014. View Article : Google Scholar : PubMed/NCBI
|
5
|
Fowler KB and Boppana SB: Congenital
cytomegalovirus (CMV) infection and hearing deficit. J Clin Virol.
35:226–231. 2006. View Article : Google Scholar : PubMed/NCBI
|
6
|
Cannon MJ: Congenital cytomegalovirus
(CMV) epidemiology and awareness. J Clin Virol. 46 Suppl 4:S6–S10.
2009. View Article : Google Scholar : PubMed/NCBI
|
7
|
La Rosa C and Diamond DJ: The immune
response to human CMV. Future Virol. 7:279–293. 2012. View Article : Google Scholar : PubMed/NCBI
|
8
|
Söderberg-Nauclér C: HCMV microinfections
in inflammatory diseases and cancer. J Clin Virol. 41:218–223.
2008. View Article : Google Scholar : PubMed/NCBI
|
9
|
Varnum SM, Streblow DN, Monroe ME, Smith
P, Auberry KJ, Pasa-Tolic L, Wang D, Camp DG II, Rodland K, Wiley
S, et al: Identification of proteins in human cytomegalovirus
(HCMV) particles: The HCMV proteome. J Virol. 78:10960–10966. 2004.
View Article : Google Scholar : PubMed/NCBI
|
10
|
Feire AL, Roy RM, Manley K and Compton T:
The glycoprotein B disintegrin-like domain binds beta 1 integrin to
mediate cytomegalovirus entry. J Virol. 84:10026–10037. 2010.
View Article : Google Scholar : PubMed/NCBI
|
11
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
12
|
Anders CK and Carey LA: Biology,
metastatic patterns, and treatment of patients with triple-negative
breast cancer. Clin Breast Cancer. 9 Suppl 2:S73–S81. 2009.
View Article : Google Scholar : PubMed/NCBI
|
13
|
Lawson JS and Heng B: Viruses and breast
cancer. Cancers (Basel). 2:752–772. 2010. View Article : Google Scholar : PubMed/NCBI
|
14
|
Newton R, Ziegler J, Bourboulia D,
Casabonne D, Beral V, Mbidde E, Carpenter L, Reeves G, Parkin DM,
Wabinga H, et al: The sero-epidemiology of Kaposi's
sarcoma-associated herpesvirus (KSHV/HHV-8) in adults with cancer
in Uganda. Int J Cancer. 103:226–232. 2003. View Article : Google Scholar : PubMed/NCBI
|
15
|
Fagundes CP, Glaser R, Alfano CM, Bennett
JM, Povoski SP, Lipari AM, Agnese DM, Yee LD, Carson WE III, Farrar
WB, et al: Fatigue and herpesvirus latency in women newly diagnosed
with breast cancer. Brain Behav Immun. 26:394–400. 2012. View Article : Google Scholar : PubMed/NCBI
|
16
|
Breathnach O, Donnellan P, Collins D,
McNicholas W and Crown J: Cytomegalovirus pneumonia in a patient
with breast cancer on chemotherapy: Case report and review of the
literature. Ann Oncol. 10:461–465. 1999. View Article : Google Scholar : PubMed/NCBI
|
17
|
Harkins LE, Matlaf LA, Soroceanu L, Klemm
K, Britt WJ, Wang W, Bland KI and Cobbs CS: Detection of human
cytomegalovirus in normal and neoplastic breast epithelium.
Herpesviridae. 1:82010. View Article : Google Scholar : PubMed/NCBI
|
18
|
Isaacson MK and Compton T: Human
cytomegalovirus glycoprotein B is required for virus entry and
cell-to-cell spread but not for virion attachment, assembly, or
egress. J Virol. 83:3891–3903. 2009. View Article : Google Scholar : PubMed/NCBI
|
19
|
Cobbs C, Khan S, Matlaf L, McAllister S,
Zider A, Yount G, Rahlin K, Harkins L, Bezrookove V, Singer E and
Soroceanu L: HCMV glycoprotein B is expressed in primary
glioblastomas and enhances growth and invasiveness via PDGFR-alpha
activation. Oncotarget. 5:1091–1100. 2014. View Article : Google Scholar : PubMed/NCBI
|
20
|
Costanza B, Umelo IA, Bellier J,
Castronovo V and Turtoi A: Stromal Modulators of TGF-β in Cancer. J
Clin Med. 6:72017. View Article : Google Scholar
|
21
|
Derynck R, Akhurst RJ and Balmain A:
TGF-beta signaling in tumor suppression and cancer progression. Nat
Genet. 29:117–129. 2001. View Article : Google Scholar : PubMed/NCBI
|
22
|
Cao Y, Liu X, Zhang W, Deng X, Zhang H,
Liu Y, Chen L, Thompson EA, Townsend CM Jr and Ko TC: TGF-beta
repression of Id2 induces apoptosis in gut epithelial cells.
Oncogene. 28:1089–1098. 2009. View Article : Google Scholar : PubMed/NCBI
|
23
|
Cipriano R, Kan CE, Graham J, Danielpour
D, Stampfer M and Jackson MW: TGF-beta signaling engages an
ATM-CHK2-p53-independent RAS-induced senescence and prevents
malignant transformation in human mammary epithelial cells. Proc
Natl Acad Sci USA. 108:8668–8673. 2011. View Article : Google Scholar : PubMed/NCBI
|
24
|
Ewen ME, Sluss HK, Whitehouse LL and
Livingston DM: TGF beta inhibition of Cdk4 synthesis is linked to
cell cycle arrest. Cell. 74:1009–1020. 1993. View Article : Google Scholar : PubMed/NCBI
|
25
|
Lebrun JJ: The dual role of TGFβ in human
cancer: From tumor suppression to cancer metastasis. ISRN Mol Biol.
2012:3814282012. View Article : Google Scholar : PubMed/NCBI
|
26
|
Derynck R, Zhang Y and Feng XH:
Transcriptional activators of TGF-beta responses. Cell. 95:737–740.
1998. View Article : Google Scholar : PubMed/NCBI
|
27
|
Kang Y: Pro-metastasis function of TGFbeta
mediated by the smad pathway. J Cell Biochem. 98:1380–1390. 2006.
View Article : Google Scholar : PubMed/NCBI
|
28
|
Uhl M, Aulwurm S, Wischhusen J, Weiler M,
Ma JY, Almirez R, Mangadu R, Liu YW, Platten M, Herrlinger U, et
al: SD-208, a novel transforming growth factor beta receptor I
kinase inhibitor, inhibits growth and invasiveness and enhances
immunogenicity of murine and human glioma cells in vitro and in
vivo. Cancer Res. 64:7954–7961. 2004. View Article : Google Scholar : PubMed/NCBI
|
29
|
Mohammad KS, Javelaud D, Fournier PG,
Niewolna M, McKenna CR, Peng XH, Duong V, Dunn LK, Mauviel A and
Guise TA: TGF-beta-RI kinase inhibitor SD-208 reduces the
development and progression of melanoma bone metastases. Cancer
Res. 71:175–184. 2011. View Article : Google Scholar : PubMed/NCBI
|
30
|
Dunn LK, Mohammad KS, Fournier PG, McKenna
CR, Davis HW, Niewolna M, Peng XH, Chirgwin JM and Guise TA:
Hypoxia and TGF-beta drive breast cancer bone metastases through
parallel signaling pathways in tumor cells and the bone
microenvironment. PLoS One. 4:e68962009. View Article : Google Scholar : PubMed/NCBI
|
31
|
Ishiyama M, Miyazono Y, Sasamoto K, Ohkura
Y and Ueno K: A highly water-soluble disulfonated tetrazolium salt
as a chromogenic indicator for NADH as well as cell viability.
Talanta. 44:1299–1305. 1997. View Article : Google Scholar : PubMed/NCBI
|
32
|
Massagué J and Gomis RR: The logic of TGFβ
signaling. FEBS Lett. 580:2811–2820. 2006. View Article : Google Scholar : PubMed/NCBI
|
33
|
Mitchell DA, Xie W, Schmittling R, Learn
C, Friedman A, McLendon RE and Sampson JH: Sensitive detection of
human cytomegalovirus in tumors and peripheral blood of patients
diagnosed with glioblastoma. Neuro Oncol. 10:10–18. 2008.
View Article : Google Scholar : PubMed/NCBI
|
34
|
Scheurer ME, Bondy ML, Aldape KD, Albrecht
T and El Zein R: Detection of human cytomegalovirus in different
histological types of gliomas. Acta Neuropathol. 116:79–86. 2008.
View Article : Google Scholar : PubMed/NCBI
|
35
|
Soroceanu L, Akhavan A and Cobbs CS:
Platelet-derived growth factor-alpha receptor activation is
required for human cytomegalovirus infection. Nature. 455:391–395.
2008. View Article : Google Scholar : PubMed/NCBI
|
36
|
Vanarsdall AL, Wisner TW, Lei H,
Kazlauskas A and Johnson DC: PDGF receptor-α does not promote HCMV
entry into epithelial and endothelial cells but increased
quantities stimulate entry by an abnormal pathway. PLoS Pathog.
8:e10029052012. View Article : Google Scholar : PubMed/NCBI
|
37
|
Utrera-Barillas D, Valdez-Salazar HA,
Gómez-Rangel D, Alvarado-Cabrero I, Aguilera P, Gómez-Delgado A and
Ruiz-Tachiquin ME: Is human cytomegalovirus associated with breast
cancer progression. Infect Agent Cancer. 8:122013. View Article : Google Scholar : PubMed/NCBI
|
38
|
Soroceanu L and Cobbs CS: Is HCMV a tumor
promoter? Virus Res. 157:193–203. 2011. View Article : Google Scholar : PubMed/NCBI
|
39
|
Muraoka RS, Dumont N, Ritter CA, Dugger
TC, Brantley DM, Chen J, Easterly E, Roebuck LR, Ryan S, Gotwals
PJ, et al: Blockade of TGF-beta inhibits mammary tumor cell
viability, migration, and metastases. J Clin Invest. 109:1551–1559.
2002. View Article : Google Scholar : PubMed/NCBI
|
40
|
Tang B, Vu M, Booker T, Santner SJ, Miller
FR, Anver MR and Wakefield LM: TGF-beta switches from tumor
suppressor to prometastatic factor in a model of breast cancer
progression. J Clin Invest. 112:1116–1124. 2003. View Article : Google Scholar : PubMed/NCBI
|
41
|
Fynan TM and Reiss M: Resistance to
inhibition of cell growth by transforming growth factor-beta and
its role in oncogenesis. Crit Rev Oncog. 4:493–540. 1993.PubMed/NCBI
|
42
|
Liu X, Sun Y, Constantinescu SN, Karam E,
Weinberg RA and Lodish HF: Transforming growth factor beta-induced
phosphorylation of Smad3 is required for growth inhibition and
transcriptional induction in epithelial cells. Proc Natl Acad Sci
USA. 94:10669–10674. 1997. View Article : Google Scholar : PubMed/NCBI
|
43
|
Petersen M, Pardali E, van der Horst G,
Cheung H, van den Hoogen C, van der Pluijm G and Ten Dijke P: Smad2
and Smad3 have opposing roles in breast cancer bone metastasis by
differentially affecting tumor angiogenesis. Oncogene.
29:1351–1361. 2010. View Article : Google Scholar : PubMed/NCBI
|
44
|
Iyer S, Wang ZG, Akhtari M, Zhao W and
Seth P: Targeting TGFbeta signaling for cancer therapy. Cancer Biol
Ther. 4:261–266. 2005. View Article : Google Scholar : PubMed/NCBI
|
45
|
Han G, Lu SL, Li AG, He W, Corless CL,
Kulesz-Martin M and Wang XJ: Distinct mechanisms of
TGF-beta1–mediated epithelial-to-mesenchymal transition and
metastasis during skin carcinogenesis. J Clin Invest.
115:1714–1723. 2005. View Article : Google Scholar : PubMed/NCBI
|
46
|
Korpal M, Yan J, Lu X, Xu S, Lerit DA and
Kang Y: Imaging transforming growth factor-beta signaling dynamics
and therapeutic response in breast cancer bone metastasis. Nat Med.
15:960–966. 2009. View Article : Google Scholar : PubMed/NCBI
|
47
|
Jiang HL, Sun HF, Gao SP, Li LD, Hu X, Wu
J and Jin W: Loss of RAB1B promotes triple-negative breast cancer
metastasis by activating TGF-β/SMAD signaling. Oncotarget.
6:16352–16365. 2015.PubMed/NCBI
|
48
|
Burke HG and Heldwein EE: Crystal
structure of the human cytomegalovirus glycoprotein B. PLoS Pathog.
11:e10053002015. View Article : Google Scholar : PubMed/NCBI
|